OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Sp starting to recover - clearly there are some holders who are prepared to sell into good news:

LONDON (AFX) - Oxford Biomedica PLC said pre-clinical trials of RetinoStat concluded the treatment for loss of vision may be effective in alleviating cases of age-related macular degeneration (AMD).

Macular degeneration is a retinal degenerative disease that causes progressive loss of central vision, and is the most common cause of vision loss in individuals over the age of 55. Wet AMD accounts for about 10 pct of cases, but is responsible for 90 pct of severe vision loss.

AMD is caused by abnormal blood vessel growth in the eye, leading to distortion and loss of central vision. RetinoStat uses a LentiVector system to deliver genes to the retina that block the formation of new blood vessels which cause the ailment.

The pre-clinical data to be presented by the company in Florida today show RetinoStat was well tolerated and achieved the two efficacy endpoints. Importantly, the results show a statistically significant improvement in reducing the area of abnormal blood vessel growth and blood vessel leakage occurring in cases of wet AMD.

Around 15 million people in the US have some form of AMD, with 1.6 million experiencing wet AMD. Presently, over 500,000 people worldwide lose their sight annually from the disease.

In the second half of 2005, Oxford BioMedica expects to complete additional pre-clinical efficacy studies and prepare for clinical trials, pencilled in to start 2006-07.

'RetinoStat is meeting its design objectives and is on track for clinical development,' chief executive Professor Alan Kingsman said. 'AMD is a devastating disease and there is a real unmet need for a long-lasting efficacious product.'

At 8.00 am shares in Oxford Bio were unchanged at 29-1/2 pence, valuing the Oxford University spin-out at 111 mln stg.

ab/har

Bugger! Wrong again.

Cheer up pachandl,

it's up again today!

so I may sell another chunk.

I risk missing out on a proportion of my profit but heck this share has got a track record of falling back so I'll get another chance & I've still got plenty of these shares left.

Best of luck Apple - tell me after you have sold and I will take out a massive short to get the sp down for you to re-enter. All part of the service.

My finger was hovering over the button but I didn't do it today.

:-)

Collusion eh?
A bit of OUTSIDER price fixing.
Is it legal?

Apple - you need an edge or you will lose money. Outsider dealing? Hmmm, seems legal as far as I see it, otherwise all fund managers would be in prison by now. Have a great weekend.

nice tick up today, anybody with a reason why???? cant find any news on OXB

Just had a look on the uk.biz.yahoo.com website
for information on OXB. Apparently the Broker,
Panmure has placed a 'buy'recommendation on the
stock last week with a 45p price target.

Life is wonderful ya get me!

1704
yeah life is wonderful apart from i may have to sell these babies in a couple of weeks due to house move and raising capital. however, i have made a tidy profit so cant complain. just wish i could stay for the longhaul.

accord
Not sure whats up with MoneyAM's news feed, but here's
todays RNS.


RNS Number:0160M
Oxford Biomedica PLC
09 May 2005


FOR IMMEDIATE RELEASE 9 MAY 2005


OXFORD BIOMEDICA RECEIVES EUROPEAN PATENT FOR TROVAX(R) COVERING 5T4 TUMOUR
ANTIGEN-TARGETED IMMUNOTHERAPY

Oxford, UK: 9 May 2005 - Oxford BioMedica (LSE: OXB), the leading gene therapy
company, today announced that the European Patent Office has granted a key
patent (No. EP1036091), that provides broad protection for Oxford BioMedica's
lead product, TroVax. This is one of several granted and pending patents that
protect the Company's ownership of the 5T4 tumour antigen. The granted patent
covers immunotherapy products directed against 5T4 and includes specific claims
to the use of viral delivery systems in 5T4-targeted vaccines.

5T4 is a tumour associated antigen that is expressed on a wide range of tumour
types. A number of published immunohistochemical studies have demonstrated that
there is a high incidence of 5T4 expression on colorectal cancer, renal cell
carcinoma and breast cancer, amongst others. 5T4 expression is frequently
correlated with poor prognosis and metastatic spread. Overall, 5T4 is present on
more than 75% of human solid tumours, yet it is not found on any essential
organs. These characteristics make 5T4 an ideal target for immunotherapy
treatment in a wide range of cancer types.

Commenting on the issued patent Oxford BioMedica's Chief Executive, Professor
Alan Kingsman said: "The newly granted patent, together with several other
granted and pending patents, provide protection for our lead product, TroVax, as
well as next generation cancer vaccines based on the 5T4 antigen. This positions
Oxford BioMedica as one of the leading players in the emerging field of cancer
immunotherapy. TroVax has potential utility as a treatment for most solids
tumours, hence, the potential to be a major commercial opportunity for the
Company."

-Ends-

FILTHY POOR: i thank you, good news is better than none at all.

Thanks FILTHY POOR

Going well so far today!

I nearly sold a few more last Friday, glad I didn't.

Looks too good to be true though.

Anything that looks too good to be true normally is but as I am a greedy bugger I am hanging on (for fame & fortune, or total bankruptcy).

Possibly due to the imminent ASCO meeting in Florida?

I believe that during one of the webcasts, Prof. Kingsman said that some more
data for Trovax would be presented at ASCO.

Also might explain why there was no accompanying statement following the AGM, as the abstracts for papers presented will be embargoed until the start of the conference.

Possibly....

Thanks mcp2

mcp2 - I believe that OXB have asked for a modified embargo on the information that will be presented at ASCO. There is a facility for this to occur. This request was acceded to last week which "might" suggest that OXB will put out an rns tomorrow (if they consider it worthwhile). However, I am not holding my breath.

Bugger - how did I miss this at 10.30???????

Oxford Biomedica PLC
12 May 2005


FOR IMMEDIATE RELEASE 12 MAY 2005

OXFORD BIOMEDICA TO PRESENT NEW TROVAX(R) DATA
FROM PHASE II TRIALS IN COLORECTAL CANCER AT THE 2005 ASCO
ANNUAL MEETING ON 15 MAY


Oxford, UK: 12 May 2005 - Oxford BioMedica (LSE: OXB), the leading gene therapy
company, today announced that new data from the Phase II trials of TroVax, its
cancer immunotherapy, in colorectal cancer will be presented on 15 May at the
2005 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in
Orlando, Florida, USA, on 13-17 May 2005. Details are as follows:

"An Open Label Phase II Study of MVA Expressing the Tumour Antigen 5T4 Given in
Conjunction with Chemotherapy: Safety and Immunogenicity Before, During and
After Chemotherapy." (Abstract #30642)

Session: Developmental Therapeutics, Immunotherapy
Sunday 15 May, 8:00 am - 12:00 noon, Level 2, Hall C, H10

This abstract may be accessed online at http://www.asco.org/ at the conclusion
of the meeting.

The presentation describes two Phase II trials of TroVax in first line treatment
of metastatic colorectal cancer alongside irinotecan-based (IFL) and
oxaliplatin-based (FOLFOX) chemotherapy. Oxford BioMedica previously reported
encouraging results from the trials in March 2005. The new data include analysis
of immune responses and clinical benefit.

Enrolment in the trials was completed in September 2004 with 36 patients
recruited. The trials are on track to report full safety and immunological data
as well as final tumour response statistics in the second half of 2005. Patient
survival, which can be compared to historical controls, will be reported once
the median survival has been reached in the two trials. This is anticipated in
early 2006.

Commenting on the ASCO presentation of Phase II results for TroVax, Oxford
BioMedica's Chief Scientific Officer, Dr Sue Kingsman, said: "We are very
pleased with the progress of TroVax in clinical trials and look forward to
presenting new data at ASCO

Reduction by about 2.5m in an existing holding:

Oxford Biomedica PLC
12 May 2005


Oxford BioMedica plc (the 'Company')

Notification of Major Interests in Shares

The Company has received notification today from Man Financial Limited that on
11 May 2005 it was the beneficial owner of 27,800,600 Oxford BioMedica plc 1p
ordinary shares. This represents 7.42% of the presently issued share capital of
the Company, which stands at 374,850,009 shares.

12 May 2005

Looks as if they're reducing further or someone else is - two 635k sells gone through this morning.